You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR CEREBYX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CEREBYX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00510783 ↗ IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures Completed UCB Pharma Phase 4 2007-07-01 This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a history of seizures can be involved. The patient must present to the emergency department within 4 hours of a seizure. The purpose of this study is to compare these three drugs, phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs can prevent another seizure in the next 24 hours. We are also looking for any possible side effects.
NCT00510783 ↗ IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures Completed Emory University Phase 4 2007-07-01 This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a history of seizures can be involved. The patient must present to the emergency department within 4 hours of a seizure. The purpose of this study is to compare these three drugs, phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs can prevent another seizure in the next 24 hours. We are also looking for any possible side effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CEREBYX

Condition Name

Condition Name for CEREBYX
Intervention Trials
Tonic-clonic Seizure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CEREBYX
Intervention Trials
Emergencies 1
Seizures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CEREBYX

Trials by Country

Trials by Country for CEREBYX
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CEREBYX
Location Trials
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CEREBYX

Clinical Trial Phase

Clinical Trial Phase for CEREBYX
Clinical Trial Phase Trials
Phase 4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CEREBYX
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CEREBYX

Sponsor Name

Sponsor Name for CEREBYX
Sponsor Trials
UCB Pharma 1
Emory University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CEREBYX
Sponsor Trials
Industry 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.